Moonlake Immunotherapeutics · NASDAQ:MLTX
Moonlake Immunotherapeutics — Investor Day (June 2022)
77 slides from Moonlake Immunotherapeutics's investor day presentation, Jun 7, 2022
Slide 1: MoonLake
O MoonLake MoonLake —
Slide 2: Disclaimer
Disclaimer O Moontake Forward Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our e
Slide 3: For the session today
For the session today -\ rg J. Santos da Silva Pho Kristian Reich mp, Pho (CEO, Founder) (CSO, Founder) ain James Krueger Matthias Bodenstedt MD, PhD (CFO) Chris Ritchlin MD, MPH Agenda Time Topic (speaker) 20 Perspective on MoonLake (Jorge) 30’ KOL View: Hidradenitis Suppurativa (Jim) 30° KOL View:
Slide 4: Perspective on MoonLake
Perspective on MoonLake
Slide 5: Revolutionizing Immunotherapy through Nanobody technology
Dll po you still Antibody } ee olutionizing Immunothe J” trough Nanobody’® technology Rev! "apy MoonLake O Founded in 2021 in Switzerland © Nanobody® technology licensed in initial private round O Unique molecule & MoA with sonelokimab, tri-specific IL-17A & IL-1F Nanobody® O Public on Nasdaq in Apr
Slide 6: Three Key Messages
Three Key Messages 1 We are developing sonelokimab (SLK), a Nanobody® with potential to elevate treatment outcomes in inflammatory diseases, via IL-17A and IL-17F inhibition 2 Our development program has an established track record of clinical progress and expands SLK’s potential across Dermatology
Slide 7: Do you still Antibody?
Do you still Antibody? O Moontake Nanobodies® are much smaller than They can be designed to have multiple and traditional antibodies different binding domains Y CG, ex Binds IL-17F QO + j > > Y GC) (eee ter Conventional IgG Heavy-chain-only — Nanobody® single- Binds IL-I7A (~150kDa) antibody (~ 85kD
Slide 8: It's all about the dimers
It’s all about the dimers O Mmoontake Illustrative IL-I7A and IL-17F Nanobody Sonelokimab y Receptor activation IL-T7RC N-17RA IL-17A and IL-17F function as dimers (A/A, A/F, or F/F) to drive Not all IL-17-targeting therapeutics can inhibit IL-17A/A, inflammation through activation of the IL-17RA/RC
Slide 9: SLK is the only Nanobody among IL-17, IL-23 & TNF inhibitors
SLK is the only Nanobody® among IL-17, IL-23 & TNF inhibitors O moontake The key MoA - IL-17 inhibition The key molecules SLK Sonelokimab or “SLK” Secukinumab — Bimekizumab * MoonLake’s molecule: the only tri-specific Nanobody®, ~3x smaller than a monoclonal Ixekizumab antibody, one of only two drug
Slide 10: Only two competitors in IL-17A and IL-17F...but very different competitors
Only two competitors in IL-17A and IL-17F...but very different competitors © moontake Sonelokimab (SLKk) Bimekizumab (BkZ) 40 KDa Ilustrative (based on another mAb) 1 2 150 KDa Anti-Li7e YZ ( ES . ‘Anti-IL17A&F = Smaller fully active biologic =La 1 «= 2x different IL-17 binding domains = 1x IL-17 bi
Slide 11: Potential for higher efficacy of SLK versus the IL-17 market leader
PASI 100 (%) Potential for higher efficacy of SLK versus the IL-17 market leader Efficacy comparison between SLK and market leader Cosentyx in Phase II (%) 59 60 57 | THE LANCET *,@® 1L17A/F nanobody sonelokimab in patients with plaque 50 “psoriasis: a multicentre, randomised, placebo-controlled, Th
Slide 12: SLK has a differentiated safety profile to date
SLK has a differentiated safety profile to date O moontake THE LANCET *4 @® 1L17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, SS So SS phase 2b study mete fan Eas Sema! ces re Gee See a senda Malte A ks teh Soyemee ‘ito 3000) "teow! ‘teow
Slide 13: IL-17 inhibition is expected to lead in a significantly growing $40bn+ market
IL-17 inhibition is expected to lead in a significantly growing $40bn+ market © moontake Global sales USD Bn 44.3 Prevalence (%) Psoriatic Arthritis = Driven by IL-17s with rates of 11%+ growth CD = IL-23s falling short ¥ “03 = Mostly IL-17 (incl. IZO) and IL-23 development (also JAKs) 31.7 a HS Hid
Slide 14: Inhibition of IL-17A & F across select indications underscores SLK potential
Inhibition of IL-17A & F across select indications underscores SLK potential © moontake Psoriatic Arthritis (PsA) ACR 50 (%) at week 24 A&F ne) 62 ADA 39 SEC 5 —— Superior pert rn ance on ACR 20 & movin 1 to ACR50 1 Ritclin CT, etal Lancot 2020;395:427-40; 2 Moaso PJ, et al Jemee GB otal, presented
Slide 15: The MoA and SLK continue to ramp-up momentum
The MoA and SLK continue to ramp-up momentum O Mmoontake Best target in HS (survey Feb 2022, n=35, %) KOL views (Apr 2022) MoA CD40 a = IL-17 now 1 of 3 established targets in HS — “no doubt the IL-17 drugs will come into use” IL-ta 4 = “For higher levels of disease clearing, better activity with A&
Slide 16: Broader competition in HS, less so in PsA — SLK has unique properties
Broader competition in HS, less so in PSA — SLK has unique properties Hidradenitis suppurativa no x So (SUNRISE (BE HEARD | IL-17A and IL-17F = INCTO3713632] and INCT04242446] andl _ inhibitor (SC) os 3 SUNSHINE {NCT04242498) Phase 2 cdi Qa [NCT03713619]) IL-17A and IL-17F N= 220 and N= 891 IL-17A i
Slide 17: The penetration advantage
The penetration advantage O Moontake Albumin binding matters in inflammation 24h after iv nanobodies; Effects of anti-tumor necrosis factor (anti-TNF) VHH protein constructs on the clinical progression of established collagen- induced arthritis (CIA) Coppieters K et al., Arthritis Rheum 54, 1856-66
Slide 18: Differentiation: SLK has the potential to combine properties like no other asset
Differentiation: SLK has the potential to combine properties like no other asset O Moontake Safety “IL-17A & F inhibition without the infections” Affinity “Strong on A, balanced on F” Penetration “8x smaller + Albumin binding”
Slide 19: SLK has the potential to unlock value in IL-17A & F Inflammatory Diseases
SLK has the potential to unlock value in IL-17A & F Inflammatory Diseases © moontake Immediate portfolio of indications for SLK Psoriatic Arthritis (-0.5% prevalence) Psoriasis (~3% prevalence) 7 \N — GN (~0.3% prevalence), 7 aus 4 \, eee Wa Hidradenitis Cine we Ne Suppurativa inflammatory} (-1% pre
Slide 20: SLK shows a potentially superior benefit-risk profile in Psoriasis
SLK shows a potentially superior benefit- risk profile in Psoriasis (incl. vs 174) SLK is a distinctive molecule with enhanced enrichment in deep skin & joints and binding of targets with better-than-mAb affinity and specificity —a potentially winning benefit-risk profile across IL-17A & F diseases
Slide 21: We are advancing an extended global Phase program in Derm & Rheum
We are advancing an extended global Phase 2 program in Derm & Rheum © moontoke Approach to clinical design Global Phase 2 program = MoonLake advancing global, large Phase 2 trials in Dermatology and Rheumatology «First trials started was for Hidradenitis Suppurativa, a disease with very high unmet n
Slide 22: MoonLake is led and supported by a highly experienced group
MoonLake is led and supported by a highly experienced group O Moontake Leadership team Board of Directors Investors in de-SPAC Kara Lassen CORMORANT (Roche) B V F ASSET MANAGEMENT PARTNERS LP. Jorge Santos da Silva (CEO, Founder, Board Director) Prof. Kristian Reich Catherine Moukheibir ih @ (CSO, F
Slide 23: In summary
In summary fo. O oO MoonLake MoonLake is well on its way as a public biotech, one year after being founded The innovative Nanobody® sonelokimab is a promising (and largely de-risked) molecule with the potential to revolutionize care It moves the clinical paradigm beyond traditional antibodies, to di
Slide 24: The KOL view: Hidradenitis Suppurativa
The KOL view Hidradenitis Suppurativa
Slide 25: Evolving Pathways & Therapeutic Landscape in Hidradenitis Suppurativa
Evolving Pathways & Therapeutic Landscape in Hidradenitis Suppurativa Professor James G. Krueger (MD, PhD) D. Martin Carter Professor in Clinical Investigation Senior Attending Physician and Laboratory Head, Investigative Dermatology Co-director, Center for Clinical and Translational Science Chief E
Slide 26: HS is a chronic, inflammatory, recurrent, severely debilitating skin disease
HS is a chronic, inflammatory, recurrent, severely debilitating skin disease © © moontake = HS is characterized by inflammatory nodules and abscesses complicated by the formation of pus-discharging dermal tunnels! ma 5 * a Ps ~ = High symptom burden; chronic pain, large amounts of purulent secretion
Slide 27: Only one approved biologic — TNF-a inhibitor adalimumab (Humira)
Only one approved biologic — TNF-a inhibitor adalimumab (Humira®) O meontake Hl Placebo [1 Adalimumab 40mg weekly Adalimumab Week 12 HiSCR50 responses! Adalimumab Week 12 DLQI 0/1 responses' 100 100 ° S 90 2 3 $31% (p<0.001 70 60 | 416% (p=0.003 9 41.8% 1 260% 27.6% 80 70 60 50 40 30 +5% (p<0.05) +5
Slide 28: Need to elevate treatment goals in HS & assess impact on draining tunnels
Need to elevate treatment goals in HS & assess impact on draining tunnels © moontake 70 HiSCR75 Medical Need * % reduction from baseline in AN count (inflammatory 60 ee nodules and abscesses), with no increase from baseline in abscess or draining tunnels + Number of nodules (x1) + number of abscesse
Slide 29: Snapshot of HS Drug Development Landscape
Snapshot of HS Drug Development Landscape O moontake Category Agent Target Phase NCT Primary endpoint HiSCR50 Monoclonal ‘ . NCT03713632 (primary endpoint . . antibody - Secukinumab eves 3 _NCT03713619 met, data to be No animal models of HS exist, reported) making delineation of the key Bimekizumab
Slide 30: Inhibition of IL-17A and IL-17F has the potential to reach a greater threshold of clinical response
Inhibition of IL-17A and IL-17F has the potential to reach a greater O Mecntate threshold of clinical response (HISCR75, HiSCR90) Week 12 HiSCR responses m Placebo =ADA = BKZ DADA reference arm & 805 S 70 4 67 x 604 59 oD $ 50 4 42 = 40 4 J 4 28 2 30 26 o 204 a& 104 0 4 154 153 ‘ 163 163 ‘ 18 40 18
Slide 31: Increasing scientific evidence supports IL-17A and IL-17F-mediated inflammation in HS
Increasing scientific evidence supports IL-1 7A- and IL-1 7F-mediated inflammation as a key driver of the pathogenesis of HS IL-17A and IL-17F expressing cells abundant in HS4 = Elevated serum IL-17 levels in patients with Hst3 = Upregulation of IL-17A and IL-17F mRNA in HS tissue"-3 = Compared with
Slide 32: In HS, predominance towards Type17 T-cells that discretely produce IL-17F
In HS, there is a predominance towards Type17 T-cells that discretely O Mecntate produce IL-17F compared to IL-17A" 1L17A_1IL17F 4 PsO Es 24 The dots are single cells - Red: Express IL-17A ° UMAP_1 azA. 147 Waza_1La7F Green: Express IL-17F 6 s 6 Yellow: IL-17A and IL-17F ta af 7 ¥ 6 Ne Ne Hs §. a g
Slide 33: Key role of IL-17F in activation of epithelialized tunnels and neutrophil influx in HS
Key role of IL-17F in activation of epithelialized tunnels and neutrophil O Woontake influx in HS IL-17F is present throughout HS lesions Draining tunnels are deep HS lesions that express IL- 17A and IL-17F' IL17F Log2(Expression/nARP) Inhibition of IL17 signaling in patients using the IL- 17RA anta
Slide 34: Efficacy in Psoriasis is no prediction of efficacy in HS
Efficacy in Psoriasis is no prediction of efficacy in HS O moontake Guselkumab (IL-23p19 inhibitor) Psoriasis HS 100 100 = = 380 73 8 80 g 3 a a 60 = 60 51 £ D 3 ¢ 45 2 S 39 40 8 40 & 3S g o 520 2 20 = ® é 3 = 0 + a otf N=174 N=329 N=62 N=60 N=59 Placebo GUS Placebo GUS GUS 100mg SC Wk 0, 4, then q8
Slide 35: Inhibition of IL-1a has shown potential efficacy in an open label study
Inhibition of IL-1a has shown potential efficacy in an open label study O meontake Biology of IL-1a in HS still unclear = Bermekimab (anti-TNF failed) = Bermekimab (anti-TNF naive) 63 61 Patients achieving HiSCR50 (%) N= 24 18 24 18 24 18 Week 2 Week 6 Week 12 Bermekimab (IL-1 inhibitor) 400 mg QW P
Slide 36: Proposed mechanism of Type17 T-cell activation in HS vs Psoriasis
Proposed mechanism of Type17 T-cell activation in HS vs Psoriasis O moontake PSORASIS ramemse)—e}— com HIDRADENITIS SUPPURATIVA }
Slide 37: Recap of today's learnings
Recap of todays learnings O Mmoontake 1. Need for higher treatment goals in HS and measurement of tunnels 2. IL-17F is the dominant cytokine in HS 3. IL-1a role and potential in HS still unclear 4. IL-23p19 inhibition failed; may have limited role in HS relative to psoriasis
Slide 38: Which pathway would you pick?
Which pathway would you pick? O Moontake TNF-a Established pathway in HS IL-17A and IL-17F Several data sets supporting IL-17 targeting: Secukinumab, Bimekizumab and Brodalumab * Secukinumab met Phase 3 primary endpoint (HiSCR50) = Bimekizumab Phase 3 close to completion « Brodalumab impact on tunne
Slide 39: Optimizing IL-17A and IL-17F inhibition for the management of HS
Optimizing IL-17A and IL-17F inhibition for the management of HS O meontake Sonelokimab Complete Clearance Psoriasis’ Phase 2b 90 = ¢ Smaller size vs. monoclonal antibodies r...~«d 60 57 0 (%) 8 A Ss ae eiburnin + 2x different IL-17 binding domains + Independent Albumin binding 34 Anti-IL-17A . or I
Slide 40: The KOL view: Psoriatic Arthritis
The KOL view Psoriatic Arthritis
Slide 41: Psoriatic Arthritis: The latest view
Psoriatic Arthritis: The latest view Professor Christopher Ritchlin (M.D, MPH) University of Rochester Medical Center, Rochester, New York, USA
Slide 42: PsA is a complex and heterogeneous disease
PsA is a complex and heterogeneous disease O Moontake The clinical features of PsA are diverse, comprising both musculoskeletal and non-musculoskeletal manifestations! Frequency of active PsA domain presentations (®) @, (CorEvitas/CORRONA registry, N = 2,617) N (ED Most patients with PsA have multi-
Slide 43: Early intervention is needed
Early intervention is needed O Moontake PsA affects up to 30% of patients with psoriasis! and involves a complex interaction of risk factors, psoriasis-related factors, and associations with comorbidities and EAMs?2 Genetics Hi Association Psoriasis e@ Risk factor i | Psoriasis-related factor Psoria
Slide 44: Several available therapies ...
Several available therapies '” ... O Moontake * methotrexate, sulfasalazine, cyclosporine, leflunomide, apremilast * etanercept, infliximab, adalimumab, golimumab, certolizumab pegol * ustekinumab * secukinumab, ixekizumab * abatacept tofacitinib, upadacitinib * guselkumab, rizankizumab
Slide 45: ...yet still significant unmet medical need
...yet still significant unmet medical need'® O woontate 70 60 Divergent skin vs. tissues Unmet medical need responses driven by: ii 1)Tissue penetration? 2) Differential cytokine expression ; [. profiles across skin vs. joints? ADA? SKB? UST# —GUS® = GUS® PASI90 ACR70 Skin Joints All timepoints at
Slide 46: However, more molecules in development
However, more molecules in development O meontake Deucravacitinib' Small Molecule TYkK2 inhibitor Sonelokimab Nanobody® IL-17A and IL-17F inhibitor Bimekizumab? Pe Monoclonal Antibody Izokibep IL-17A and IL-17F inhibitor Antibody Mimetic IL-17AVA inhibito Tiidrakizumab® Monoclonal Antibody IL-23p19
Slide 47: PB SF
RA p=0.16 PB SF — NO 1's ON S'S S}199 1 +809 UIYWM S199 +VZE-11 % x ?p) fae Cc = <x ra xe. & 3 a = id 8 — (1) Oo & &£ Bo faa} > -_ oO S ve) a — op) NONSTOMON TK O Cc = S sjleo 1 +809 o UIYIIM $1199 +¥Z1-T1 % (qv) > co ce) WL 2 3 ° 2 Bg 8 a 0 F (ee) — Q anantanero O . ml ra s[l29 1 +809 x UIYIIM $118
Slide 48: IL-17F is the dominant IL-17 cytokine in PsA with and without Psoriasis
IL-17F is the dominant IL-17 cytokine in PsA with and without Psoriasis O moontake Baseline levels of IL-17F in patients with PsA Baseline levels of IL-17A and IL-17F in patients with Psoriasis compared with matched healthy controls from compared with PsA with and without Psoriasis cross different C
Slide 49: IL-17 plays a central role in the pathophysiology of PsA
IL-17 plays a central role in the pathophysiology of PsA and and can be O woontake expressed by multiple cell types independently of IL-23 IL-7 IL-9 CD8+Tcells CD4+T cells MAIT cells iNKT cells VOT cells ILCs Inflamed joints and entheses ea in spondyloarthritis Jo IL-17A and IL-17F + Inflammation *
Slide 50: Bimekizumab demonstrates efficacy in PsA with strengths on skin manifestations
Bimekizumab demonstrates efficacy in PsA with strengths on skin O Moontake manifestations Placebo [fill Bimekizumab !)) Adalimumab Bimekizumab ACR50 response rates by trial, % Bimekizumab PASI100 response rates by trial, % 70 70 59% (n=176) Q =] 3 sat? 48% 46% 1% 46% (n=26) Feat eat (n=431) (0=140)
Slide 51: Recent Izokibep data raises questions about the drivers of efficacy in joint disease
Recent Izokibep data raises questions about the drivers of efficacy in O Moontoke joint disease Placebo fill Bimekizumab [| Izokibep (80mg Q2W) Bimekizumab- Phase 3 Izokibep- Phase 2 Product » IL-17A and IL-F inhibitor » IL-17A/A inhibitor characteristics = Traditional monoclonal antibody = Antibody
Slide 52: Enthesitis — A challenging domain
Enthesitis — A challenging domain O Moontake Enthesitis is inflammation of the enthesis, the * Enthesitis is a key feature of PsA, occurring in a third of sites where tendons insert into bone! patients 2 Achilles * Presence of enthesitis has shown to be associated with higher disease activity, disab
Slide 53: Where exactly are the entheses?
Where exactly are the entheses? Supraspinatus Lateral Epicondyle Iliac Crest ~ Br Trochanter Patellar/Quad Plantar Fascia/AT
Slide 54: Enthesitis — Putting tissue penetration to the test
Enthesitis — Putting tissue penetration to the test O Moontake Izokibep Enthesitis Resolution’ Leeds Enthesitis Index =0 (LEI=0) 88% 90 4 (n=17) 0 (%) Patients achieving LEI Noh A DN =) So o Recent data support the relevance of tissue penetration in the treatment of enthesitis 3S Small sub-groups; a
Slide 55: In Summary
In Summary O Moontake 1. PsAis a complex heterogenous disease that requires a complete solution 2. IL-17A and IL-17F are central to PSA pathophysiology 3. Several IL-17s in development all with different physical chemical properties 4. Recent data releases at EULAR highlight the importance of IL-17A
Slide 56: Future Outlook
Future Outlook O Moontake Very recent data from EULAR with IL-17-inhibitors in development prompt the following questions; Can we optimize IL-17A and IL-17F inhibition? Are there certain molecule characteristics e.g size and albumin binding that could make a molecule specifically successful in PSA?
Slide 57: Clinical Development Update
Clinical Development Update
Slide 58: The main messages on Clinical Development
The main messages on Clinical Development 4 | The KOL views clearly point to key role for IL- 17A & F inhibition, as well as the need for tissue- penetrant and targeted high-affinity molecules 2| Aunique role for IL-17F in skin and joint inflammation, that can now be managed for long-term disease co
Slide 59: IL-17F is produced by different cells — need for specific IL-17F inhibition
IL-17F is produced by different cells — need for specific IL-17F inhibition Plasmacytoid dendritic cells Monocytes "Hinks TSO, Zhang XW. Front Front Immunol 2020;11 585134 nol 2020;11:1014 *Provine NM, etal. Sience. 2021;371:521-26 Cole S, et al Fro a8 MAIT cells'!:2.3 CD8at or DN, CD45RA-CD45RO* CD
Slide 60: As in HS, IL-17F a dominant IL-17 cytokine in lesional PsA
As in HS, IL-17F a dominant IL-17 cytokine in lesional PsA O Mmoontake Accumulation of IL-17F in synovial tissue in PsA patients! ve 3 | Notes 4 |OD/mm? = Same proportional difference of IL-17F versus IL-17A in patients treated with adalimumab? IL-A7A 19'297 1O0D/mm? = IL-17F also significantly elev
Slide 61: Arthritic joint assessment suggests SLK efficacy in deep tissue
Arthritic joint assessment suggests SLK efficacy in deep tissue O woontake Arthritic joint assessment for SLK' Clinical improvement with SLK versus mAb? Collagen-induced arthritis 70 —o- Vehicle Exp IL-17A & IL-17F mAb 10mg/kg = SLK 2.8mg/kg Arthritis score (All animals) oO & T T T 7 Immunization 0
Slide 62: Science into care: Role for SLK in long-term disease control
Science into care: Role for SLK in long-term disease control O meontake Main findings B D British journal of Dermatology SMPROWIRG PATIONT OUTCOSE I SOM BIEEASE WORLD E = Disease modification: 20% of responders at week 24 do not require re-treatment to maintain full clearance at week 44, retreatment
Slide 63: Recap: We are driving two global Phase 2 trials in our program
Recap: We are driving two global Phase 2 trials in our program O moontake to Last Patient Follow-up, DB lock,, LF, Development & Ops Plan Current view : Phase Ill Phase II . —— readiness PE:12wk/24wk 4 PsA HS Phase III Phase II ——~ readiness PE:12wk/24wk HS, PsO Start fp First pote! up Other indicat
Slide 64: HS: Phase II, randomized, double-blind, placebo-controlled, 24-week study
HS: Phase II, randomized, double-blind, placebo-controlled, 24-week O woontate study of sonelokimab in patients with active moderate to severe HS Active reference period (no H2H) Screening EE Safety follow- 2 to 4 weeks Placebo-controlled Placebo/Active reference crossover up 4 weeks ——— SS oS —_w—a
Slide 65: HS: Primary and key secondary endpoints
HS: Primary and key secondary endpoints O woontate Key secondary endpoints « HiSCR50 response at Week 12 ° % Change from baseline in IHS4 * DLQI total score of 5 or below at Week 12 ¢ Patients achieving NRS30° in Patient's Global Assessment of Skin Pain at Week 12 *HiSCR7S: Clinical response per Hid
Slide 66: Status of Trial Operations as of June 4th 2022
Status of Trial Operations as of June 4" 2022 — All activities on track O Moontake HS Regulatory - FDA + Approved IRB - US * Central IRB Protocol Approval received. Site approvals in progress Regulatory/CEC/CIRB_ + All submissions performed - ROW « RA-CA/NL/POL/BL approvals received * CEC/CIRB — CA/
Slide 67: PsA: Final design of proposed Phase II PsA study (24 weeks)
PsA: Final design of proposed Phase II PsA study (24 weeks) O Moontake Screening Treatment period Cross-over period SFU (up to 4 weeks) (12 weeks) (12 weeks) (4 weeks) ——_e_—_————"— _::90—:. aayy=—_— +: ——n nnn ae Group 1 (n=40)¢ Sonelokimab Dose 1 a" sonelokimabDoseil Adalimumab 40 mg Week 12, Q2W
Slide 68: PsA: Primary and Key Secondary Endpoints
PsA: Primary and Key Secondary Endpoints O Moontake Primary endpoint » ACRS50 response? at Week 12 Key secondary endpoints » PASI100 response at Week 12 (patients with psoriasis involving 23% BSA at baseline) » ACR20 response at Week 12 Other secondary endpoints » ACR70 response at Week 12 » Minimal
Slide 69: The ambition for SLK is to win across different therapeutic scores
The ambition for SLK is to win across different therapeutic scores O Mmoontake Hidradenitis Suppurativa (HS) Psoriatic Arthritis (PsA) Conceptual Conceptual HiSCR75 ACR50 { (Ato PLC) (Ato PLC) 40, 40, ts . 35,, 30., Plus, important Plus, important measures that will allow measures that will allow fu
Slide 70: In summary
In summary oO oO MoonLake Evidence for a specific role of IL-17F in a growing number of diseases including HS, PSA and PSO Full anti-inflammatory potential and long-term disease control requires inhibition of IL-17A/A, A/F, and F/F Optimal delivery of MoA requires unique characteristics such as enha
Slide 71: Financial Overview & Guidance
Financial Overview & Guidance
Slide 72: Summary of MoonLake's corporate history
Summary of MoonLake’s corporate history O Mmoontake 2021 2022 roo) ° Oo March ‘21 April ‘21 July ‘21 October ‘21 pril ‘22 Registration SeriesAledby Registration of UK Definitive agreement with Helix Closing of De-SPAC as Swiss BVF Partners subsidiary Acauisition Corp. to enter into De- transaction a
Slide 73: De-SPAC provided >USD 150m in proceeds
De-SPAC provided >USD 150m in proceeds O Moontake Business combination with Helix = 1 De SPAC proceeds Corporate structure Acquisition Corp (SPAG sponsored in USD M 151 by Cormorant Asset Management) MLTX MoonLake Immunotherapeutics USD 151m in aggregate deal (formerly Helix Acquisition Corp) procee
Slide 74: MoonLake on a solid financial foundation with runway into 2H-2024
MoonLake on a solid financial foundation with runway into 2H-2024 O woontake Runway well into 2H-2024: cash provides runway to key clinical data readouts plus 12+ months (at zero debt) Average quarterly cash burn in the “/ow-teen millions” — next quarters elevated due to one-off expenses: O Remainin
Slide 75: Active news flow with multiple catalysts
Active news flow with multiple catalysts (HS read only 12 months out) O Mmoontake Research On IL-17A&F and tissue penetration HS readouts starting with primary endpoint read in mid 2023 Competitor readouts incl. Secukinumab, Bimekizumab, Izokipeb Other PR / Social Media Supplier partnerships Possibl
Slide 76: Our approach to Investor Relations
Our approach to Investor Relations Open and transparent communication on company strategy, direction and updates in a regulation-FD compliant manner No plans to change status as domestic filer with quarterly financial reporting and other associated filing requirements At least semi-annual event-base
Slide 77: MoonLake
MoonLake Immunotherapeutics — Investor Day (June 2022) on 6ix